GSE221329 ERK BRAF inhibition thyroid gland 1 v 6 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE221329_ERK_BRAF inhibition_thyroid gland_1_v_6_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE221329_ERK_BRAF inhibition_thyroid gland_1_v_6_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE221329_ERK_BRAF inhibition_thyroid gland_1_v_6_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE221329_ERK_BRAF inhibition_thyroid gland_1_v_6_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 5

Gene

DExD-box helicase 52

Gene

Pvt1 oncogene

Gene

PAX8 antisense RNA 1

Gene

mir-100-let-7a-2-mir-125b-1 cluster host gene

Gene

urothelial cancer associated 1

Gene

long intergenic non-protein coding RNA 2910

Gene

DUS4L-BCAP29 readthrough

Gene

long intergenic non-protein coding RNA 707

Gene

SLC16A1 antisense RNA 1

  • Gene

    small nucleolar RNA host gene 5


  • Gene

    DExD-box helicase 52



  • Gene

    PAX8 antisense RNA 1


  • Gene

    mir-100-let-7a-2-mir-125b-1 cluster host gene


  • Gene

    urothelial cancer associated 1


  • Gene

    long intergenic non-protein coding RNA 2910


  • Gene

    DUS4L-BCAP29 readthrough


  • Gene

    long intergenic non-protein coding RNA 707


  • Gene

    SLC16A1 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.